Mirum Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 25, 2026
MIRM$93.18-0.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $296,683 | $222,503 |
| Short-term investments | 86,644 | 57,812 |
| Accounts receivable | 123,330 | 78,286 |
| Inventory | 24,887 | 22,403 |
| Prepaid expenses and other current assets | 18,140 | 11,784 |
| Total current assets | 549,684 | 392,788 |
| Restricted cash | 1,482 | 425 |
| Long-term investments | 8,105 | 12,526 |
| Property and equipment, net | 1,862 | 1,139 |
| Operating lease right-of-use assets | 8,741 | 8,675 |
| Intangible assets, net | 260,921 | 249,819 |
| Other assets | 12,018 | 5,382 |
| Total assets | $842,813 | $670,754 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $9,614 | $14,618 |
| Accrued expenses and other current liabilities | 196,185 | 111,933 |
| Total current liabilities | 205,799 | 126,551 |
| Operating lease liabilities, noncurrent | 7,516 | 7,972 |
| Convertible notes payable, net, noncurrent | 309,797 | 308,082 |
| Other liabilities | 5,011 | 2,509 |
| Total liabilities | 528,123 | 445,114 |
| Commitments and contingencies | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized, and no shares issued and outstanding as of December 31, 2025 and 2024 | — | — |
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 51,896,391 and 48,338,096 shares issued and outstanding as of December 31, 2025 and 2024, respectively | 5 | 5 |
| Additional paid-in capital | 981,878 | 870,189 |
| Accumulated deficit | (667,544) | (644,181) |
| Accumulated other comprehensive income (loss) | 351 | (373) |
| Total stockholders’ equity | 314,690 | 225,640 |
| Total liabilities and stockholders’ equity | $842,813 | $670,754 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.